Forest Investor Says $25B Actavis Offer Is Insufficient
An investor in Carl Icahn-backed Forest Laboratories sued Thursday to block generic drugmaker Actavis PLC's $25 billion takeover of the company, saying the price is too low and calling the deal...To view the full article, register now.
Already a subscriber? Click here to view full article